Edge Therapeutics to Host Conference Call on November 1, 2016 to Discuss Third Quarter Financial Results
October 25 2016 - 7:00AM
Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage
biotechnology company developing novel hospital-based therapies in
the management of acute, life-threatening conditions, today
announced it will host a conference call on Tuesday, November 1,
2016 at 8:30 a.m. ET to discuss its third quarter 2016 financial
results.
The conference call will be available via phone and webcast. To
access the call, please dial (877) 388-5691, or (562) 350-0788 for
international callers, and reference participant code 4072165
approximately 15 minutes prior to the call. A replay of the call
may be accessed through November 15, 2016 on the investor section
of Edge’s website or by dialing (855) 859-2056, or (404) 537-3406
for international callers, and referencing participant code
4072165. A live webcast of the conference call will be available on
the investor relations section of Edge’s website at
www.edgetherapeutics.com.
About Edge Therapeutics, Inc.Edge Therapeutics,
Inc. is a clinical-stage biotechnology company that discovers,
develops and seeks to commercialize novel, hospital-based therapies
capable of transforming treatment paradigms for the management of
acute, life-threatening neurological conditions. EG-1962, Edge’s
lead product candidate, has the potential to fundamentally improve
patient outcomes and transform the management of aneurysmal
subarachnoid hemorrhage, which is bleeding around the brain due to
a ruptured brain aneurysm. Edge is evaluating EG-1962 in two
clinical studies: the pivotal Phase 3 NEWTON 2 study of EG-1962
delivered via external ventricular drain, and a study of direct
intracisternal administration of EG-1962. For additional
information about Edge, please visit www.edgetherapeutics.com.
Forward-Looking StatementsThis press release
and any statements of representatives of Edge Therapeutics, Inc.
related thereto that are not historical in nature contain, or may
contain, among other things, certain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements may include, without
limitation, statements with respect to Edge’s plans, objectives,
projections, expectations and intentions and other statements
identified by words such as "projects," "may," "will," "could,"
"would," "should," "believes," "expects," "anticipates,"
"estimates," “seeks,” "intends," "plans," "potential" or similar
expressions, including statements with respect to Edge’s ability to
advance its portfolio of therapies through development and towards
commercialization and the potential effects of its products. These
statements are based upon the current beliefs and expectations of
Edge’s management and are subject to significant risks and
uncertainties. Actual results may differ significantly from those
set forth in the forward-looking statements. These forward-looking
statements involve certain risks and uncertainties that are subject
to change based on various risk factors (many of which are beyond
Edge's control) as described under the heading "Risk Factors" in
Edge’s filings with the United States Securities and Exchange
Commission.
Investor Contact:
Gregory Gin
Edge Therapeutics, Inc.
Tel: 1-800-208-EDGE (3343)
Email: ir@edgetherapeutics.com
Media Contact:
Laura Bagby
6 Degrees
Tel: 312-448-8098
Email: lbagby@6degreespr.com
EDGE THERAPEUTICS, INC. (NASDAQ:EDGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
EDGE THERAPEUTICS, INC. (NASDAQ:EDGE)
Historical Stock Chart
From Sep 2023 to Sep 2024